Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Laura Kennedy, MD, PhD
Vanderbilt University/Ingram Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Emory University/ Winship Cancer Institute
Atlanta, Georgia, United States
Kevin Kalinsky, MDNot, yet, recruiting - University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Adam Brufsky, MDNot, yet, recruiting - Vanderbilt University/ingram Cancer Center
Nashville, Tennessee, United States
Laura Kennedy, MD, PhDRecruiting - University of Texas, Southwestern
Dallas, Texas, United States
Carlos Arteaga, MDNisha Unni, MDRecruiting - Baylor College of Medicine
Houston, Texas, United States
Bora Lim, MDNot, yet, recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 May 2024
- Primary completion
- 30 Apr 2030
- Completion
- 30 Apr 2031
- Last update posted
- 9 Sept 2025
- Registered enrollment
- 30
- Registry id
- NCT05919108
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.